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Congenital nephrogenic diabetes insipidus (NDI) is a conformation disease resulting from 
protein misfolding. Ninety percent of mutations result from the inactivating mutations of the 
arginine vasopressin receptor 2 (AVPR2) gene transmitted in an X-linked fashion, blocking 
the response to vasopressin, resulting in the inability to concentrate urine. Clinical features 
include polyuria, polydispsia, dehydration, and hypernatremia. They are generally more 
severely in affected males but present variably in females due to skewed inactivation of 
the X chromosome. We describe a case of a 40-year-old woman with a history of Type 
2 diabetes mellitus, hyperlipidemia, and obesity, who presents with debilitating polyuria 
since the age of 5 with no clear diagnosis. Interestingly, her son was diagnosed with 
NDI. Genetic testing revealed that she was heterozygous for the Val88Met mutation in 
the AVPR2 gene while her son was hemizygous for the same. The patient has since 
been successfully treated with diuretics and a low solute diet. We highlight that although 
X-linked NDI patients are mostly males, it should be considered in symptomatic females 
to prevent delays in the diagnosis. Conformational diseases such as NDI are presently 
the subject of research using pharmacological chaperones to restore proper receptor 
membrane localization and function.
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Case Report
We describe a 40-year-old Hispanic female with a history significant for diabetes mellitus Type 2, 
hyperlipidemia, and obesity, who was referred to the nephrology clinic for evaluation of polyuria. Her 
family history was significant for diabetes insipidus diagnosed in her son at 8 years of age. This patient 
has been evaluated for polyuria and polydipsia since the age of 5 years with no definite diagnosis. She 
reports drinking 4–5 gallons of water every day due to extreme thirst. She also admits to debilitating 
nocturia, urinating about 10 times every night.
Her laboratory tests revealed a serum sodium in the range of 138–145 mEq/L, serum osmolality 
of 286 mOsm/kg, with a concomitant urine osmolality of 171 mOsm/kg. The patient’s hemoglobinA1C 
was elevated at 8.9, though her urine did not reveal glucosuria. Her urine osmolality ranged from 72 
to 171 mOsm/kg measured on multiple occasions. Her urinalysis was also significant for proteinuria 
with a urine protein-to-creatinine ratio ranging from 400 to 800 mg/g. Urine electrolytes revealed a 
urine sodium of <20 mmol/L, urine chloride of 20 mmol/L, and urine potassium of 50 mmol/L. The 
patient’s CT scan of the abdomen was consistent with a recently passed stone.
Given the patient’s strong family history and findings, the patient and her son underwent genetic 
testing. The patient was found to be heterozygous for Val88Met mutation in the AVPR2 gene while 
her son was found to be hemizygous for the same.
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The patient has since been successfully treated with hydrochlo-
rothiazide (HCTZ) at 12.5 mg once daily and a low solute diet with 
significant improvement in her symptoms.
This patient has given her consent to report her case in a 
publication.
Discussion
Nephrogenic diabetes insipidus (NDI) is a rare genetic disease 
caused most commonly by mutations in two different genes. 
Though the exact prevalence is unknown, Arthus et al. found that 
the prevalence of NDI in Quebec, Canada to be 8.8 per 1,000,000 
males. Interestingly, the Nova Scotia and New Brunswick popula-
tion exhibited an incidence that was six times higher (1).
In 90% of patients, the affected gene is arginine vasopressin 
receptor 2 (AVPR 2), whereas the remainder of patients have been 
shown to have had a defect in the aquaporin 2 (AQP2) gene (2). 
Both of these receptors play a crucial role in the concentration 
of urine by facilitating water reabsorption through the action of 
anti-diuretic hormone (ADH), also known as vasopressin.
The AVPR2 gene is located in the chromosome region Xq28; 
it has three exons and two introns and is inherited in an X-linked 
mode of transmission (3). This gene encodes for vasopressin 2 (V2) 
receptors located in the basolateral membrane of the principal cell. 
The V2 receptor is a three-dimensional protein consisting of 371 
amino acid residues that form 7 transmembrane, 4 extracellular, 
and 4 cytoplasmic domains (4). These receptors mediate the action 
of vasopressin in the collecting ducts. Binding to vasopressin leads 
to the formation of cAMP, which activates protein kinase and 
initiates a phosphorylation cascade; this results in the exocytic 
insertion AQP2receptors in the luminal membrane, thereby 
increasing water permeability and reabsorption (5).
More than 200 mutations of the AVPR2 gene have been reported 
in the Human Gene Mutation Database (6). Missense mutations 
were responsible for 55.83%, of which the amino acids arginine 
and tyrosine were most commonly mutated (7). The majority of the 
affected individuals are diagnosed in the first year of life, whereas 
those with partial and heterozygote for X-linked NDI may present 
with symptoms later in life (8).
A study from Montreal of 90 families with AVPR2 muta-
tions demonstrated that most have a full phenotype, while only 
three families have a mild version (9). In males with the AVPR2 
mutation, the phenotype is characterized by severe dehydration, 
hypernatremia, hyperthermia, mental and physical retardation, 
and kidney failure. Women with this genetic defect are heterozy-
gous and exhibit variable degrees of clinical symptoms. This varied 
phenotypic expression may be related to the skewed inactivation 
of X chromosome (10).
Our patient harbors the V88M mutation. V88M mutation 
produces V2 receptors which are trapped intracellularly. Pan et al. 
initially described V88M as a sequence variant (11) but was later 
regarded V88M as a disease causing mutation (12). Arthus et al. 
studied two severely affected females with the V88M mutation who 
demonstrated extreme skewing in favor of the paternal X chromo-
some (1). The study also estimated that about 1% of females who is 
heterozygous for the AVPR2 mutation may exhibit a phenotype as 
severe as that of NDI males. He concluded that although X-linked 
NDI patients are mostly males, it should also be included in the 
differential diagnosis of symptomatic females to prevent delays 
in the diagnosis.
The AQP2 gene, on the other hand, is located on chromosome 
region 12q13 and has 4 exons and 3 introns. The gene codes for a 
polypeptide of 271 amino acids and has six membrane spanning 
domains (4). The AQP2 water channel usually lies dormant in 
the intracellular vesical membranes. Upon binding of vasopres-
sin to the V2 receptor, it fuses with the luminal membrane of 
the principal cells. About 35 mutations in the AQP2 gene have 
been reported that follow an autosomal recessive or autosomal 
dominant mode of inheritance. Mutations in the recessive form 
of NDI are located throughout the gene, resulting in misfolded 
proteins that are retained in the endoplasmic reticulum. On the 
contrary, mutations in the dominant form of this disorder are 
localized to the carboxyl terminus of gene and the resultant AQP2 
mutants are properly folded, but missorted (13). The dominant 
form of inheritance is known to have mild clinical manifestations 
as compared to the recessive form (6).
Renal ultrasound is recommended to evaluate for hydrone-
phrosis, dilatation of the urinary tract, and megacystitis. Urinary 
tract dilatation is a well-known but rare complication attributed 
mainly to the large volume of urine produced. Polyuria usually 
causes no more than mild to moderate hydronephrosis; however, 
rare cases of severe urinary tract dilatation have been reported 
(14). If a disease causing mutation has been identified in a family, 
then appropriate genetic testing and counseling should be offered 
to symptomatic individuals and high risk pregnancies.
General management of NDI involves a low salt, low protein 
diet with administration of diuretics and non-steroidal anti-
inflammatory drugs (NSAIDS). Paradoxically, thiazide diuretics 
can cause a state of mild volume contraction so that more sodium 
and water can be reabsorbed in the proximal tubules and less water 
is delivered to the vasopressin-sensitive site of the principal cell 
(15). Prostaglandins may alleviate symptoms by reducing the 
glomerular filtration rate, increasing proximal tubule or distal 
tubule sodium reabsorption, and exerting an inhibitory effect on 
the action of vasopressin (16, 17). A study that compared the treat-
ment with HCTZ alone, HCTZ/triamterene, HCTZ/amiloride, and 
HCTZ/acemetacin (NSAID) demonstrated the superiority of the 
HCTZ/amiloride combination in that it prevented hypokalemia 
and metabolic alkalosis (18). In infants, special attention must be 
paid to minimize polyuria, hypernatremia, and volume depletion. 
In adults, treatment depends on the clinical symptoms of polyuria 
since electrolyte abnormalities and volume depletion are generally 
protected by the intact thirst mechanism. In patients complicated 
by both diabetes mellitus and insipidus, as in our patient, it may be 
difficult to discriminate between which entity is truly contributing 
intractable polyuria. Thus, the first step is to achieve strict glycemic 
control to avoid the exacerbation of unmitigated glucosuria before 
employing strategies to treat NDI.
Since the cloning of the V2R gene in 1992 (3), developing the 
use of chaperones, a rescue mechanism to correct mutations, is 
possible. Chaperones are pharmacological ligands, which act by 
binding to and stabilizing specific conformations of their receptors. 
To this end, Morello and colleagues have successfully used vaso-
pressin analogs capable of acting as chaperones to rescue misfolded 
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mutant V2 receptors to their proper folding and function (19). 
A recent human pilot trial also showed that a low-affinity agent 
for V2R significantly decreased the 24 h urine volume and water 
intake (20). Unfortunately, due to the potential interference with 
the cytochrome P450 metabolic pathway and hepatic toxicity, this 
trial was terminated at the phase II level. Despite this, the concept 
appears to be valid and research using this “chaperone” method 
continues.
To conclude, congenital NDI is a rare genetic disorder in 
which the majority of the affected are males who are diagnosed 
during infancy. However, carrier females have variable phenotype 
causing them to remain undiagnosed early in life. Their quality 
of life could be affected from distressing symptoms like extreme 
polyuria and polydipsia, putting them at a risk for dehydration. 
Strong suspicion should be maintained in the setting of clas-
sical symptoms and family history. Genetic testing should be 
encouraged to confirm the diagnosis. At present, management 
of these patients includes correcting of confounding diagnoses, 
adequate water intake, use of diuretics and NSAIDs, as well as a 
low solute diet.
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